Selling your practice to your own clinicians

Almost every owner considers it. The clinicians already know the clients, the culture survives, and nobody has to explain to a caseload why the practice was sold to a company they have never heard of.

It is also the deal most likely to fall apart, and usually for the same three reasons.

Why owners want it

The appeal is rarely financial, and it is worth being honest about that up front.

Continuity is the real draw. A buyer from outside will change things — that is usually why they bought. An internal buyer inherits the practice you built and mostly keeps running it. For an owner who spent a decade being responsible for these clinicians and these clients, that matters more than the last ten percent of the price.

There is a practical argument too. Internal buyers need less diligence, because they already know where the problems are. The process is shorter, quieter, and far less likely to leak to your staff mid-negotiation — because your staff is the buyer.

Why it usually pays less

Two structural reasons, and neither is about your practice being worth less.

Your clinicians cannot pay what a platform can. A consolidator is buying earnings it will fold into a larger operation, and it is comparing your practice to other acquisitions. A clinician is buying a job and a business with their own savings and a bank loan. The ceiling is set by what a lender will advance against the practice’s cash flow, which is usually well below what a strategic buyer would pay.

The multiple itself is often lower. An internal buyer is frequently one clinician or a small group, which means the practice they are buying is more owner-dependent the day after closing than it was the day before — they now hold both a caseload and the management. That is the same owner-dependency discount covered in what multiple do therapy practices sell for, applied to the buyer instead of the seller.

Expect an internal sale to land toward the lower end of the range for your size and structure. If continuity is worth that gap to you, it is a rational trade. Just make it deliberately rather than discovering it in month four.

The financing problem, which is the real one

This is where these deals actually die.

Your clinicians almost certainly do not have the purchase price in cash. That leaves three routes, and most internal sales use some combination:

Bank or SBA financing. A lender underwrites the practice’s cash flow and the buyer’s personal position. Approval is slower than either of you expects, and the loan amount is capped by debt-service coverage — which is a polite way of saying the practice has to demonstrably produce enough to repay the loan and pay the new owner. Practices where the departing owner was also the largest producer often fail this test, because the earnings the lender is looking at leave with you.

A seller note. You finance part of the price yourself and are paid over several years out of the practice’s future earnings. This is extremely common in internal sales and it changes what you are actually agreeing to: you are no longer selling a practice, you are lending money to people who now control the asset securing the loan. If the practice struggles, you are both the creditor and the person who trained them.

A staged buy-in. They purchase a minority stake, then more over time. It lowers the barrier and it lengthens the entanglement — you remain a co-owner of a business you are trying to leave, with someone whose judgement you can no longer overrule.

None of these are wrong. All three mean the money arrives later and depends on the practice continuing to perform after you stop running it.

What the gap actually looks like

Worth doing the arithmetic, because the number surprises people in both directions.

Take a group with $450,000 of SDE where the owner still directs clinically. On the tables in what multiple do therapy practices sell for, that sits at 2.6× — call the practice worth roughly $1.17 million to an outside buyer with everything in order.

Now price the same practice for two of your clinicians. They are buying it together, they will both keep caseloads, and neither has run the business side. That is the owner-dependent column rather than the director column, which at this size is 2.0× — about $900,000.

Then the financing. A lender will not advance the whole price, and it will underwrite against earnings that have to cover the loan and pay two new owners. Suppose they raise $630,000 between an SBA loan and their savings. The remaining $270,000 has to come from somewhere, and in an internal sale it almost always comes from you — a seller note paid out of the practice’s earnings over five or so years.

So the honest comparison is not $1.17 million against $900,000. It is $1.17 million, mostly at closing, against $630,000 at closing and $270,000 that depends on people you trained continuing to run a practice well enough to pay you.

That may still be the right trade. Plenty of owners take it deliberately. But it is a different decision from the one the headline numbers describe, and it is worth making it with the second version in front of you.

What to sort out before you raise it with them

Once you have said it out loud, you cannot unsay it. A clinician who knows the practice may be for sale behaves differently — and if the conversation collapses, you have a key person who now knows you are leaving.

Before that conversation:

Know your number. Not a hopeful one. If you have not run a valuation, do it first, so the discussion starts from earnings and a multiple rather than from a figure you both feel your way toward.

Decide what you will accept and in what form. A lower price paid in cash at closing is often worth more than a higher price paid over five years by people whose ability to pay depends on a practice you no longer control.

Talk to your CPA and an attorney first. Internal sales carry structural questions an outside sale does not — how the entity transfers, what happens to your personal guarantees on the lease and any credit lines, and whether the buy-in triggers anything in your existing agreements.

Work out who is actually the buyer. “The clinicians” is not a buyer. One clinician who wants it and three who feel obliged is a governance problem you are handing your successor.

What it does not solve

An internal sale does not fix owner dependency — it relocates it.

If the practice runs on your judgement, it will run on theirs, and the same fragility that discounted your valuation now sits on someone with less experience and a loan. The work described in what buyers look for — documented systems, group-held payer contracts, signed clinician agreements, a clinical director who is not the owner — makes an internal sale more likely to succeed, not just more valuable to an outsider.

That work is worth doing regardless of who ends up buying. It is the only preparation that pays off in every direction, including the one where you decide not to sell at all.

---

Nothing here is legal, tax or accounting advice. Internal sales in particular have structural consequences that depend on your entity and your state — have that conversation with your own advisers before you have it with your team.

The valuation calculator is free and takes about four minutes. Knowing the number before the conversation is the whole point.